Posted on 22/02/2010 in Pharmaceutical Company Product News GlaxoSmithKline has received the backing of the European Medicines Agency's (EMEA's) Committee for Medicinal Products for Human Use (CHMP) for two potentially promising new cancer drugs.
The CHMP has endorsed both the breast cancer drug Tyverb and the kidney cancer treatment Votrient, both of which are orally administered, for approval by the EMEA.
Both of these treatments have undergone a series of clinical trials, from which the company was able to collate evidence of their safety and effectiveness.
Eddie Gray, president of GlaxoSmithKline Pharmaceuticals in Europe, welcomed the number of positive recommendations the healthcare firm has been granted by the CHMP in recent months.
This includes the positive opinion received last month for Arzerra, its treatment for refractory chronic lymphocytic leukaemia.
Mr Gray said: "We are proud that the rapid pace of our development programme is delivering products that may make a difference for those patients who continue to try and overcome these two types of cancers."Other news stories from 22/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
